Download PDF
Semin Thromb Hemost
DOI: 10.1055/s-0044-1787841
Review Article

Current Diagnosis of von Willebrand Disease in Italy: 3 Years Following the Release of the International Guidelines

Augusto B. Federici
1   Hematology and Transfusion Medicine, School of Medicine of the University of Milan, L. Sacco University Hospital, Milan, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The American Society of Hematology–International Society on Thrombosis and Haemostasis–National Hemophilia Foundation–World Federation of Hemophilia 2021 International Guidelines (IGL) on von Willebrand disease (VWD) have pointed out many challenges, mainly in the diagnostic approach of VWD patients. To determine the impact of these IGL on the current clinical and laboratory diagnosis of Italian VWD patients, we have recently conducted a survey among 43 centers affiliated with the Italian Association of Hemophilia Centers (AICE). Directors and colleagues responsible for the management of VWD patients were invited to report in a detailed questionnaire how IGL recommendations about the assessment of the specific activities of von Willebrand Factor (VWF) could be applied at their local sites. Results from such a survey showed that bleeding assessment tools, VWF antigen, and factor VIII procoagulant are currently in use in all centers. The automated assays for platelet-dependent VWF activity with or without ristocetin described in IGL have been used since 2021 in 37/43 (86%) centers. Among other laboratory tests, VWF collagen binding, ristocetin-induced platelet agglutination, multimeric analysis, VWF propeptide, VWF:FVIII binding assay were available in 49, 63, 26, 7, and 28% of AICE, respectively. Analyses of VWF gene defects are available only at 3/43 (7%) centers. Desmopressin (DDAVP) infusion trials at diagnosis, with measurements of VWF activities at 1 and 4 hours post-DDAVP, is currently performed at 38/43 (88%) centers. Based on this information, a simplified clinical diagnosis using a few automated tests before and after DDAVP has been proposed. Such a diagnostic approach will be validated prospectively in a large cohort of Italian VWD patients.

Keywords

von Willebrand factor - bleeding assessment tools - VWF activities - laboratory diagnosis of VWD - biological response to DDAVP


Publication History

Article published online:
01 July 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Leebeek FWG, Eikenboom JCJ. Von Willebrand's Disease. N Engl J Med 2016; 375 (21) 2067-2080
    CrossrefPubMedGoogle Scholar
  • 2 Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69 (02) 454-459
    CrossrefPubMedGoogle Scholar
  • 3 Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123 (06) 893-898
    CrossrefPubMedGoogle Scholar
  • 4 Federici AB, Castaman G, Mannucci PM. Italian Association of Hemophilia Centers (AICE). Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 2002; 8 (05) 607-621
    CrossrefPubMedGoogle Scholar
  • 5 Laffan M, Brown SA, Collins PW. et al. The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10 (03) 199-217
    CrossrefPubMedGoogle Scholar
  • 6 Pasi KJ, Collins PW, Keeling DM. et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10 (03) 218-231
    CrossrefPubMedGoogle Scholar
  • 7 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
    CrossrefPubMedGoogle Scholar
  • 8 Federici AB, Bucciarelli P, Castaman G. et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost 2011; 37 (05) 511-521
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Federici AB, Bucciarelli P, Castaman G. et al. The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. Blood 2014; 123 (26) 4037-4044
    CrossrefPubMedGoogle Scholar
  • 10 Abbonizio F, Arcieri R. Associazione Italiana Centri Emofilia (AICE), Giampaolo A. Registro Nazionale delle Coagulopatie Congenite. Rapporto 2018; 20 (14) 1-18
    PubMedGoogle Scholar
  • 11 O'Sullivan JM, Tootoonchian E, Ziemele B. et al. Von Willebrand disease: gaining a global perspective. Haemophilia 2023; 29 (04) 1104-1112
    CrossrefPubMedGoogle Scholar
  • 12 Corrales-Medina FF, Federici AB, Srivastava A. et al. A need to increase von Willebrand disease awareness: vwdtest.com—a global initiative to help address this gap. Blood Rev 2023; 58: 101018
    CrossrefPubMedGoogle Scholar
  • 13 Connell NT, Flood VH, Brignardello-Petersen R. et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5 (01) 301-325
    CrossrefPubMedGoogle Scholar
  • 14 Rodeghiero F, Castaman G, Tosetto A. et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005; 3 (12) 2619-2626
    CrossrefPubMedGoogle Scholar
  • 15 Castaman G, Rodeghiero F, Tosetto A. et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2006; 4 (10) 2164-2169
    CrossrefPubMedGoogle Scholar
  • 16 Tosetto A, Rodeghiero F, Castaman G. et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4 (04) 766-773
    CrossrefPubMedGoogle Scholar
  • 17 Goodeve A, Eikenboom J, Castaman G. et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). Blood 2007; 109 (01) 112-121
    CrossrefPubMedGoogle Scholar
  • 18 James PD, Notley C, Hegadorn C. et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109 (01) 145-154
    CrossrefPubMedGoogle Scholar
  • 19 Federici AB, Mannucci PM, Castaman G. et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113 (03) 526-534
    CrossrefPubMedGoogle Scholar
  • 20 Castaman G, Tosetto A, Federici AB, Rodeghiero F. Bleeding tendency and efficacy of anti-haemorrhagic treatments in patients with type 1 von Willebrand disease and increased von Willebrand factor clearance. Thromb Haemost 2011; 105 (04) 647-654
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Castaman G, Federici AB, Tosetto A. et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10 (04) 632-638
    CrossrefPubMedGoogle Scholar
  • 22 Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. J Thromb Haemost 2009; 7 (08) 1418-1421
    CrossrefPubMedGoogle Scholar
  • 23 Biss TT, Blanchette VS, Clark DS. et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire. J Thromb Haemost 2010; 8 (05) 950-956
    CrossrefPubMedGoogle Scholar
  • 24 Rodeghiero F, Tosetto A, Abshire T. et al; ISTH/SSC joint VWF and Perinatal/Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8 (09) 2063-2065
    CrossrefPubMedGoogle Scholar
  • 25 Ruggeri ZM. Von Willebrand factor: looking back and looking forward. Thromb Haemost 2007; 98 (01) 55-62
    PubMedGoogle Scholar
  • 26 Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. von Willebrand factor Subcommittee of the Standardization and Scientific Committee of the International Society for Thrombosis and Haemostasis. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13 (07) 1345-1350
    CrossrefPubMedGoogle Scholar
  • 27 Federici AB. Current and emerging approaches for assessing von Willebrand disease in 2016. Int J Lab Hematol 2016; 38 (Suppl. 01) 41-49
    CrossrefPubMedGoogle Scholar
  • 28 Favaloro EJ, Pasalic L. Laboratory diagnosis of von Willebrand disease in the age of the new guidelines: considerations based on geography and resources. Res Pract Thromb Haemost 2023; 7 (05) 102143
    CrossrefPubMedGoogle Scholar
  • 29 Lattuada A, Preda L, Sacchi E, Gallo L, Federici AB, Rossi E. A rapid assay for ristocetin cofactor activity using an automated coagulometer (ACL 9000). Blood Coagul Fibrinolysis 2004; 15 (06) 505-511
    CrossrefPubMedGoogle Scholar
  • 30 Cabrera N, Moret A, Caunedo P. et al. Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor-induced platelet agglutination method. Haemophilia 2013; 19 (06) 920-925
    CrossrefPubMedGoogle Scholar
  • 31 Lawrie AS, Stufano F, Canciani MT, Mackie IJ, Machin SJ, Peyvandi F. A comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia 2013; 19 (02) 338-342
    CrossrefPubMedGoogle Scholar
  • 32 Stufano F, Lawrie AS, La Marca S, Berbenni C, Baronciani L, Peyvandi F. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen. Haemophilia 2014; 20 (01) 147-153
    CrossrefPubMedGoogle Scholar
  • 33 Patzke J, Althaus H, Obser T. et al. Evaluation of a new VWF activity assay based on GPIba in the absence of ristocetin. Haemostesiologie 2010; 30: P07-3
    PubMedGoogle Scholar
  • 34 Flood VH, Gill JC, Morateck PA. et al. Gain-of-function GPIb ELISA assay for the molecular and clinical biology of VWD. Blood 2011; 117: e67-e74
    CrossrefPubMedGoogle Scholar
  • 35 Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83 (01) 127-135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Federici AB, Canciani MT, Forza I, Cozzi G. Ristocetin cofactor and collagen binding activities normalized to antigen levels for a rapid diagnosis of type 2 von Willebrand disease—single center comparison of four different assays. Thromb Haemost 2000; 84 (06) 1127-1128
    PubMedGoogle Scholar
  • 37 Flood VH, Gill JC, Friedman KD. et al; Zimmerman Program Investigators. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin Chem 2013; 59 (04) 684-691
    CrossrefPubMedGoogle Scholar
  • 38 Haberichter SL, Castaman G, Budde U. et al. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008; 111 (10) 4979-4985
    CrossrefPubMedGoogle Scholar
  • 39 Eikenboom J, Federici AB, Dirven RJ. et al; MCMDM-1VWD Study Group. VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood 2013; 121 (12) 2336-2339
    CrossrefPubMedGoogle Scholar
  • 40 van Genderen PJ, Boertjes RC, van Mourik JA. Quantitative analysis of von Willebrand factor and its propeptide in plasma in acquired von Willebrand syndrome. Thromb Haemost 1998; 80 (03) 495-498
    PubMedGoogle Scholar
  • 41 Federici AB, Mazurier C, Berntorp E. et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. Blood 2004; 103 (06) 2032-2038
    CrossrefPubMedGoogle Scholar
  • 42 Castaman G, Lethagen S, Federici AB. et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. Blood 2008; 111 (07) 3531-3539
    CrossrefPubMedGoogle Scholar
  • 43 Laffan MA, Lester W, O'Donnell JS. et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (04) 453-465
    CrossrefPubMedGoogle Scholar
  • 44 Federici AB. Towards a more automatic and rapid laboratory diagnosis of von Willebrand disease. Thromb Res 2016; 141: 198-201
    CrossrefPubMedGoogle Scholar
  • 45 Favaloro EJ, Bonar R, Chapman K. et al. Differential sensitivity of von Willebrand factor activity assays to large and small VWF molecular weight forms: a cross-laboratory study comparing ristocetin cofactor, collagen binding and monoclonal antibody-based assays. J Thromb Haemost 2012; 10: 1043-1054
    CrossrefPubMedGoogle Scholar
  • 46 Favaloro EJ, Mohammed S, Vong R. et al. How we diagnose 2M von Willebrand disease (VWD): use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types. Haemophilia 2021; 27 (01) 137-148
    CrossrefPubMedGoogle Scholar
  • 47 Favaloro EJ. Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data. Blood Adv 2022; 6 (02) 416-419
    CrossrefPubMedGoogle Scholar
  • 48 Federici AB. Validation of a rapid diagnostic approach in inherited and acquired defects of VWF by automatic tests assessed before and after DDAVP trial: results from the Chinese-Italian CREWILACT Study. Abstract 1705265, accepted at the WFH Congress, Madrid 21–24 April 2024
    PubMedGoogle Scholar